Roche Presents Multiple Sclerosis Drug Data Ahead of Regulatory Submission

Swiss drugmaker Roche presented clinical trial data for fenebrutinib, its experimental multiple sclerosis drug, at a major conference on Tuesday as it prepares to seek regulatory approval. Three late-stage trials demonstrated that fenebrutinib can reduce relapse rates and slow progressive disability in multiple sclerosis patients. However, analysts have identified potentially worrying liver safety signals, including two drug-related deaths among patients taking fenebrutinib. The safety concerns carry particular weight given that the FDA previously rejected a multiple sclerosis therapy from Sanofi due to liver safety issues, creating uncertainty about fenebrutinib's regulatory prospects despite its demonstrated efficacy.

Fenebrutinib's efficacy in treating multiple sclerosis

• ▪Roche presented the latest data for fenebrutinib on Tuesday.
• ▪Three late-stage trials of fenebrutinib have shown the drug to be effective.
• ▪Fenebrutinib is an experimental multiple sclerosis drug developed by Roche.
• ▪Roche believes fenebrutinib can cut relapse rates in multiple sclerosis patients.
• ▪Roche believes fenebrutinib can slow the progressive disability that multiple sclerosis causes.

Safety concerns and regulatory challenges

• ▪Two drug-related deaths occurred among patients who took fenebrutinib.
• ▪Analysts have identified potentially worrying liver safety signals associated with fenebrutinib.
• ▪Roche is preparing to seek regulatory approval for fenebrutinib.
• ▪The Food and Drug Administration previously rejected a multiple sclerosis therapy developed by Sanofi due to liver safety issues.

Perspective of Roche

• ▪Roche presented fenebrutinib data at a major conference to build support for regulatory approval.
• ▪Roche considers the efficacy benefits of fenebrutinib sufficient to pursue regulatory approval despite identified safety signals.

Perspective of Analysts

• ▪Analysts compare fenebrutinib's liver safety profile to Sanofi's rejected multiple sclerosis therapy as a cautionary precedent.
• ▪Analysts view the liver safety signals associated with fenebrutinib as potentially worrying for regulatory approval prospects.

Perspective of Multiple sclerosis patients

• ▪Multiple sclerosis patients taking fenebrutinib face potential liver safety risks that have resulted in drug-related deaths.
• ▪Multiple sclerosis patients may benefit from fenebrutinib's ability to reduce relapse rates and slow progressive disability.

1 source